Table 2 Treatment response in gastric cancer patients
Total no. chemotherapy cycles | 200 |
Median | 4 |
Range | 1–9 |
Dose delivery | |
Irinotecan (%) | 94.7 |
Capecitabine (%) | 92.6 |
Enrolled patients | 55 |
Response (%) | |
CR | 1 (1.8) |
PR | 23 (41.8) |
SD | 15 (27.3) |
PD | 10 (18.2) |
NE | 6 (10.9) |
Overall response (95% CI) | 43.6% (30.2–56.9%) |
Median time to progression, month (range) | 5 (0.5–11) |
Median survival duration, month (range) | 11 (0.5–45) |
Median response duration, month (range) | 6 (0.5–9) |
